≥60岁人群接种季节性二价(原始株/奥密克戎BA.4-5)mRNA疫苗加强针对重症COVID-19的有效性:意大利2022-2023年不同奥密克戎亚变异流行期间按日历时间及接种后时间的估计
在意大利2022-2023年疫苗接种活动开始时符合接种条件的13,083,855名≥60岁人群中开展回顾性队列分析,采用多变量Cox回归估计季节性二价(原始株/奥密克戎BA.4-5)mRNA疫苗加强针对重症COVID-19的相对疫苗有效性(rVE)。rVE从2022年10-11月的64.9%(95%CI:59.8-69.4)降至2023年4-5月的22.0%(95%CI:15.4-28.0)。在奥密克戎BA.5流行阶段接种后≤90天的rVE为83.0%(95%CI:79.1-86.1),而奥密克戎XBB流行阶段为37.4%(95%CI:25.5-47.5)。
要点
- 季节性加强针rVE从2022年10-11月的64.9%降至2023年4-5月的22.0%。
- BA.5流行期接种后≤90天rVE为83.0%,XBB流行期为37.4%。
- XBB流行期接种后181-369天rVE为15.8%(95%CI:9.1-20.1)。
核心结论
- 在疫苗接种活动期间接种季节性加强针可提供针对重症COVID-19的额外保护,直至2023年4-5月,此后重症COVID-19发病率大幅降低。
- 结果提示奥密克戎XBB亚变异可能部分逃逸了针对SARS-CoV-2原始株和奥密克戎BA.4-5株的季节性加强针所提供的免疫。
研究设计与样本
- 回顾性队列分析,纳入13,083,855名在意大利2022-2023年疫苗接种活动开始时符合接种季节性加强针条件的≥60岁人群。
- 使用多变量Cox回归模型,将疫苗接种作为时依暴露,估计调整风险比(HR)及rVE=[(1-HR)×100]。
主要发现
- 季节性加强针的rVE从2022年10-11月的64.9%(95%CI:59.8-69.4)降至2023年4-5月的22.0%(95%CI:15.4-28.0),当时多数接种者(67%)接种加强针至少已4-6个月。
- 在奥密克戎BA.5亚变异流行阶段,接种后≤90天的rVE为83.0%(95%CI:79.1-86.1);在奥密克戎XBB亚变异流行阶段为37.4%(95%CI:25.5-47.5)。
- 在XBB流行阶段,接种后181-369天的rVE估计为15.8%(95%CI:9.1-20.1)。
- 在所有分析中,60-79岁人群与≥80岁人群的rVE趋势相似,但最年长组的估计值略低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Evaluating how a COVID-19 seasonal vaccination program performed might help to plan future campaigns. This study aims to estimate the relative effectiveness (rVE) against severe COVID-19 of a seasonal booster dose over calendar time and by time since administration. We conducted a retrospective cohort analysis among 13,083,855 persons aged ≥60 years who were eligible to receive a seasonal booster at the start of the 2022-2023 vaccination campaign in Italy. We estimated rVE against severe COVID-19 (hospitalization or death) of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines by two-month calendar interval and at different times post-administration. We used multivariable Cox regression models, including vaccination as time-dependent exposure, to estimate adjusted hazard ratios (HR) and rVEs as [(1-HR)X100]. The rVE of a seasonal booster decreased from 64.9% (95% CI: 59.8-69.4) in October-November 2022 to 22.0% (95% CI: 15.4-28.0) in April-May 2023, when the majority of vaccinated persons (67%) had received the booster at least 4-6 months earlier. During the epidemic phase with prevalent circulation of the Omicron BA.5 subvariant, rVE of a seasonal booster received ≤90 days earlier was 83.0% (95% CI: 79.1-86.1), compared to 37.4% (95% CI: 25.5-47.5) during prevalent circulation of the Omicron XBB subvariant. During the XBB epidemic phase, rVE was estimated at 15.8% (95% CI: 9.1-20.1) 181-369 days post-administration of the booster dose. In all the analyses we observed similar trends of rVE between persons aged 60-79 and those ≥80 years, although estimates were somewhat lower for the oldest group. A seasonal booster dose received during the vaccination campaign provided additional protection against severe COVID-19 up to April-May 2023, after which the incidence of severe COVID-19 was much reduced. The results also suggest that the Omicron XBB subvariant might have partly escaped the immunity provided by the seasonal booster targeting the original and Omicron BA.4-5 strains of SARS-CoV-2.
引用
- Fabiani M, Mateo-Urdiales A, Sacco C, et al. Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023. Vaccine. 2024. PMID: 38834428. doi:10.1016/j.vaccine.2024.05.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。